The landscape of global healthcare is currently facing a seismic shift. In recent weeks, a surge of commentary from high-profile industry leaders has emerged, with many discussions centred on the global funding crisis and its impact. These “big-hitters” are all grappling with a singular, urgent question: how should the future of multilateral health institutions be redesigned? Prominent voices include Philippe…
Tag: Medical Innovation
-
Healthcare Investment Drives Growth and Productivity
Leaders in emerging markets are under pressure. Economies are strained. Geopolitical tension is rising. Growth must be sustained. Yet policy debates often miss one core driver of national performance: health. In fact, healthcare investment drives growth by improving productivity and stability for these economies. A nation’s health is tightly linked to its economic strength. Health care is not a side…
-
Long-acting Injectable PrEP: Transforming HIV Strategies
South Africa is currently bracing for the most significant paradigm shift in its HIV response in over a decade. The national health authority has officially approved long-acting injectable pre-exposure prophylaxis (PrEP). There are plans to roll it out across the public sector in the coming year. For public health advocates, this development represents a potential turning point for prevention. It…
-
Microneedle Eyedrop Delivery System an alternative to eyedrops
A pioneering microneedle patch, designed to dissolve upon contact with the eye, could soon replace inefficient traditional eye drops. Developed by a researcher at the University of the Witwatersrand (Wits), this innovative microneedle eyedrop delivery system holds the potential to revolutionise treatment for millions facing vision loss. This is particularly impactful in underserved communities across Africa. The invention is the…
-
HIV Prevention Strategies with Lenacapavir Injection
In a decision that could fundamentally reshape the fight against HIV, the US Food and Drug Administration (FDA) has given its approval to Gilead Sciences’ lenacapavir, a groundbreaking twice-yearly injection for preventing HIV infection in adults and adolescents. Marketed under the brand name Yeztugo in the US, this innovative drug has been eagerly anticipated by both investors and HIV/AIDS activists…